EcoDrugPlus

Proteasome 26s Subunit, Non-Atpase 13

Ensembl ID : ENSPFOG00000001193
Gene Symbol: PSMD13
3 Cross references
216 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 14

Ensembl ID : ENSPFOG00000016201
Gene Symbol: PSMD14
3 Cross references
214 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 2

Ensembl ID : ENSPFOG00000013769
Gene Symbol: PSMD2
3 Cross references
222 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 6

Ensembl ID : ENSPFOG00000009973
Gene Symbol: PSMD6
3 Cross references
212 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 7

Ensembl ID : ENSPFOG00000017493
Gene Symbol: PSMD7
3 Cross references
235 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 8

Ensembl ID : ENSPFOG00000011698
Gene Symbol: PSMD8
1 Cross references
211 Possible Orthologues:

Proteasome Subunit Alpha Type-6

Ensembl ID : ENSPFOG00000012070
Gene Symbol: LOC103149670
3 Cross references
278 Possible Orthologues:

Proteasome Subunit Beta 11

Ensembl ID : ENSPFOG00000016979
Gene Symbol: PSMB11
1 Cross references
169 Possible Orthologues:

Proteasome Subunit Beta Type-6-Like

Ensembl ID : ENSPFOG00000007787
Gene Symbol: LOC103132800
3 Cross references
230 Possible Orthologues:

Proteasome Subunit Beta Type-7-Like

Ensembl ID : ENSPFOG00000003600
Gene Symbol: LOC103153226
3 Cross references
171 Possible Orthologues:

Proteasome Subunit Beta Type-9

Ensembl ID : ENSPFOG00000002976
Gene Symbol: LOC103146403
3 Cross references
201 Possible Orthologues:

Protein Arginine Methyltransferase 5

Ensembl ID : ENSPFOG00000016877
Gene Symbol: PRMT5
3 Cross references
198 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).